Quantum BioPharma Lawsuit Allegations Featured in CTV W5 Investigation on Market Manipulation

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) announced that CTV News' investigative program W5 has aired the second part of a three-part series examining the company's allegations of stock spoofing tied to its $700 million lawsuit against CIBC and RBC. The segment, reported by award-winning journalist Jon Woodward, highlights Quantum BioPharma's claims of widespread market manipulation and its impact on the company's efforts to advance Lucid-MS, a potential multiple-sclerosis treatment. CEO Zeeshan Saeed and Co-Executive Chair Anthony Durkacz reiterated their concerns about the alleged activity, noting that Canadian exchange data cited in the lawsuit points to millions of purportedly illegal orders originating from bank platforms.

The company's allegations center on what it describes as systematic market manipulation that has affected its stock price and ability to fund development of Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation in preclinical models. Myelin degradation is the underlying mechanism of multiple sclerosis, making the treatment potentially significant for patients with this neurodegenerative disorder. Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development.

Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., Quantum BioPharma is focused on the research and development of Lucid-MS. The company also maintains other business interests, including its ownership stake in Unbuzzd Wellness Inc. and strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc. The W5 investigation brings increased public attention to the complex allegations at a time when market integrity concerns are receiving heightened scrutiny from regulators and investors alike. The full press release about the W5 segment is available at https://ibn.fm/t3Tex, and the latest news and updates relating to QNTM are available in the company's newsroom at https://ibn.fm/QNTM.

The implications of this investigation extend beyond Quantum BioPharma's specific case, potentially affecting how market manipulation allegations involving major financial institutions are perceived and addressed. As the company continues its legal battle and development of Lucid-MS, the public exposure from a major investigative news program could influence both investor confidence and regulatory oversight. The third part of the W5 series is expected to provide further examination of these allegations and their broader market implications.